Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]
In development
Reference number: GID-TA11220
Expected publication date: TBC
Following discussions with the company, there remain some issues that require further consideration, so NICE has agreed to hold a second draft guidance consultation and return for a third committee discussion.